Immunomodulators Market Trends

Immunomodulators Market Trends

• The market is poised for significant growth due to the increasing adoption of immunomodulator therapy for Crohn's disease treatment. According to MedlinePlus, Western Europe and North America reported the highest prevalence of Crohn's disease in 2022, with rates ranging from 100 to 300 cases per 100,000 individuals. Additionally, in the U.S. alone, over half a million people were affected by Crohn’s disease, highlighting the demand for immunomodulator therapy.
   
• Furthermore, recent advancements in immunomodulatory therapy, such as CAR-T cell therapy and checkpoint inhibitors, have not only reduced organ rejection rates but also enhanced the ease of achieving remission, underscoring the growing advantages of these treatments.
   
• Moreover, the increasing global prevalence of multiple sclerosis, with estimates from the National Multiple Sclerosis Society indicating approximately 2.9 million individuals worldwide and nearly 1 million Americans affected, is also driving the use of immunomodulator therapy.